Boston FIRST

Boston Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on developing a diverse portfolio of high-potential therapies across multiple therapeutic areas, including immunology, oncology, and metabolic diseases. The company operates with a unique business model, acquiring or in-licensing promising clinical assets from major pharmaceutical companies and academic institutions to accelerate their development through to proof-of-concept. Its lead programs include BOS-580, a long-acting FGF21 analog for the treatment of MASH, and BOS-342, a selective IL-17C antibody for atopic dermatitis. By leveraging a lean, expert-led team and a robust network of partners, Boston Pharmaceuticals aims to efficiently bridge the gap between early discovery and late-stage clinical success.